This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Tadalafil

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Tadalafil is a phosphodiesterase type 5 inhibitor (PDE5), like sidenafil.

  • the Summary of Product Characteristics states that (1):
    • men should be started on a dose of 10mg, taken at least 30 minutes prior to sexual activity
    • if the 10mg dose does not produce an adequate effect then the dose can be increased to 20mg
    • the maximum dosing is once daily - the mean half-life is 17.5 hours
    • continuous daily dosing is discouraged - safety of prolonged daily dosing has not been established
    • the Summary of Product Characteristics recommends a dose of 10mg for men with "impaired hepatic function" and a maximum dose of 10mg for those with "severe renal impairment"
  • focusing on its phase II/III trial results, tadalafil appears to have an enhanced period of responsiveness extending out to 36 hours in 60% of men using the 20 mg dose. Efficacy across a large population of men with erectile dysfunction (ED) of various causes (n = 1112) is in accordance with the other PDE5 inhibitors at 81% (1). Side effects are generally mild-to-moderate with study drop-out rate at 1.7% in the active arm compared to 1.1% among those receiving placebo (2)

The summary of product characteristics must be consulted before prescribing this drug

Reference:

  1. Drug and Therapeutics Bulletin (2004); 42 (7): 49-52.
  2. Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2002 Nov;11(11):1605-13.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page